Amgen

Nov 21, 2017

EMA to relocate to Amsterdam by March 2019 Results of the Monday's vote for the European Medicines Agency relocation led to the emergence of Amsterdam as the new headquarters, beating the other finalists Milan and Copenhagen. Nineteen European Union member states submitted proposals for the EMA headquarters, and Mil...

Nov 10, 2017

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle-free drug delivery device and increase patient compliance rates for biologic medicines manufactured by the former compa...

Jul 18, 2017

Takeda scores blockbuster Velcade patent reprieve till 2022 In a major lift for Takeda and its aging multiple myeloma blockbuster Velcade, a U.S. appeals court overturned a ruling that invalidated a key patent, granting new exclusivity that should translate to significant sales over time. Takeda will have exclusive ...

Jun 15, 2017

Sanofi investing around $2B into biologics production over next 3 years Following the recent approval of two new biologics, Dupixent and Kevzara, and a pipeline stuffed full of large-molecule drugs, Sanofi will invest as much as €2 billion on its biologics manufacturing network over the next several years. The discl...

May 16, 2017

Novartis, slammed by Korean scandal, tweaks its ethics, compliance policies Rocked by a corruption scandal in Korea and facing a kickbacks probe in Greece, Novartis says it's strengthening and simplifying its global ethics and compliance approach. The Swiss drug giant is aiming to shift from policing to coaching, wi...

May 04, 2017

Merck beats Q1 estimates as Keytruda sales double Merck is the victim of its own success, judging from its first-quarter report. The company beat sales and earnings estimates, and it upped its guidance for the year, despite some significant suffering from generic competition. Sales of its hit immuno-oncology drug Ke...

Apr 04, 2017

Biogen triumphs in latest Tecfidera patent dispute Biogen has prevailed in a patent squabble with Denmark’s Forward Pharma over multiple sclerosis med Tecfidera—but the decision may not actually help the Big Biotech steer clear of generic rivals. The Patent Trial and Appeal Board (PTAB) ruled Friday that Forward cou...

Feb 24, 2017

Colony Stimulating Factor 1 Receptor (CSF1R) is a cell-surface protein encoded, in humans, by the CSF1R gene. CSF1R is also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115 (Cluster of Differentiation 115), and is encoded by CSF1R gene which controls the production, differentiation, and fun...

Jan 27, 2017

Payers block Kaléo's expensive EpiPen challenger Kaléo reintroduced its Auvi-Q last week at a list price of $4,500 for a two-pack in an effort to capture some market share from Mylan’s EpiPen, which is listed at about $600 for a two-pack. Auvi-Q is set to launch next month. Under Kaléo’s pricing strategy, Auvi-Q wil...

Oct 06, 2016

Bayer Partners with DelSiTech to Develop Innovative Drug Delivery Technology for Ophthalmology Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology Licence Agreement. The agreement gives Bayer’s compounds a worldwide application of DelS...